Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "SUIT-005"

From Bioblast
Line 2: Line 2:
|abbr=FNS(Oct,PM)
|abbr=FNS(Oct,PM)
|description=[[File:1OctM;2D;3P;4S;5U;6Rot-.png|300px]]
|description=[[File:1OctM;2D;3P;4S;5U;6Rot-.png|300px]]
|info='''A:''' '''short RP2''' [[File:PDF.jpg|100px|link=http://wiki.oroboros.at/images/6/64/SUIT-005.pdf|Bioblast pdf]] »[http://wiki.oroboros.at/index.php/File:SUIT-005.pdf Versions]
|info='''A:''' '''short RP2''' when [[Malate anaplerotic pathway control state |malate-anaplerotic activity]] is zero [[File:PDF.jpg|100px|link=http://wiki.oroboros.at/images/6/64/SUIT-005.pdf|Bioblast pdf]] »[http://wiki.oroboros.at/index.php/File:SUIT-005.pdf Versions]
}}
}}
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM)
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM)
::: '''[[SUIT protocol pattern]]:''' orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama
::: '''[[SUIT protocol pattern]]:''' orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama
__TOC__
__TOC__
  Communicated by [[Iglesias-Gonzalez J]] and [[Gnaiger E]] (last update 2019-01-21)
  Communicated by [[Iglesias-Gonzalez J]], [[Gnaiger E]] (last update 2019-01-26)


== DLP applications ==
== DLP applications ==
Line 16: Line 16:


== References ==
== References ==
{{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT-004]]
{{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT-005]]
|?Was published in year=Year
|?Was published in year=Year
|?Has title=Reference
|?Has title=Reference
Line 31: Line 31:


== Strengths and limitations ==
== Strengths and limitations ==
:::+ The protocol provides information on FAO capacity in the absence of other, potentially interfering pathways, both in the LEAK state and in OXPHOS.
:::* :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
:::+ FNS OXPHOS capacity comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
 
:::+ FNS ET capacity is a good estimate of overall ET capacity in many cell types.
:::+ The protocol provides information on F-OXPHOS capacity in the absence of a significant OXPHOS-capacity in the [[malate anaplerotic pathway control state]].
:::+ The presence of PM and S establishes a fully operative TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate
:::+ FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity.
:::+ PM & S reconsitutes TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate.
:::+ Application of the [[cytochrome c]] test early in the protocol ensures comparability of all states in case of any effect of c.
:::+ Application of the [[cytochrome c]] test early in the protocol ensures comparability of all states in case of any effect of c.
:::+ Reasonable duration of the experiment.
 
:::- F OXPHOS capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011).
:::- F-OXPHOS capacity may be underestimated with Oct. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) & malate increased OXPHOS-capacity by 26% (Lemuieux et al 2011).
:::- SRot(E) may be underestimated if S is not saturating.
:::- SRot<sub>''E''</sub> may be underestimated if S is not saturating.
:::- CIV activity is not measured, to save experimental
 


== Compare SUIT protocols ==
== Compare SUIT protocols ==


::::* [[SUIT-002]]
::::* [[SUIT-002]] check for malate-linked anaplerotic activity
::::* [[SUIT-002 O2 pfi D006]]


{{MitoPedia concepts
{{MitoPedia concepts

Revision as of 15:22, 26 January 2019


high-resolution terminology - matching measurements at high-resolution


SUIT-005

Description

1OctM;2D;3P;4S;5U;6Rot-.png

Abbreviation: FNS(Oct,PM)

Reference: A: short RP2 when malate-anaplerotic activity is zero Bioblast pdf »Versions

SUIT-category: FNS(Oct,PM)
SUIT protocol pattern: orthogonal 1OctM;2D;3P;4S;5U;6Rot;7Ama
Communicated by Iglesias-Gonzalez J, Gnaiger E (last update 2019-01-26)

DLP applications

1OctM;2D;2c;3P;4S;5U;6Rot;7Ama-.png SUIT-005 O2 pfi D11.png


References

MitoPedia: SUIT

Steps and respiratory states

1OctM;2D;2c;3P;4S;5U;6Rot;7Ama;8AsTm;9Azd.png

Step State Pathway Q-junction Comment - Events (E) and Marks (M)
1OctM OctML(n) F(N) FAO 1OctM
2D OctMP F(N) FAO 1OCtM;2D
2c OctMcP F(N) FAO 1OCtM;2D;2c
3P OctPMP FN F&CI 1OctM;2D;2c;3P
  • Respiratory stimulation by simultaneous action of the F-pathway and N-pathway with convergent electron flow in the FN-pathway for evaluation of an additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
4S OctPMSP FNS F&CI&II 1OctM;2D;2c;3P;4S
  • Respiratory stimulation by simultaneous action of the F-pathway, N-pathway, and S-pathway, with convergent electron flow in the FNS-pathway for reconstitution of TCA cycle function and additive or inhibitory effect of F.
  • OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.
5U OctPMSE FNS F&CI&II 1OctM;2D;2c;3P;4S;5U
6Rot SE S CII 1OctM;2D;3P;4S;5U;6Rot
7Ama ROX 1OctM;2D;3P;4S;5U;6Rot;7Ama
  • Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated either after inhibition of CIII (e.g. antimycin A, myxothiazol), CIV (e.g. Cyanide) or in the absence of endogenous fuel-substrates. Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration.
Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB


Questions.jpg


Click to expand or collaps

Strengths and limitations

  • :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
+ The protocol provides information on F-OXPHOS capacity in the absence of a significant OXPHOS-capacity in the malate anaplerotic pathway control state.
+ FNS comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum OXPHOS- and ET-capacity.
+ PM & S reconsitutes TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate.
+ Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- F-OXPHOS capacity may be underestimated with Oct. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) & malate increased OXPHOS-capacity by 26% (Lemuieux et al 2011).
- SRotE may be underestimated if S is not saturating.


Compare SUIT protocols

  • SUIT-002 check for malate-linked anaplerotic activity


MitoPedia concepts: MiP concept, SUIT protocol, Recommended 


MitoPedia methods: Respirometry